enGene Holdings Inc.ENGNNASDAQ

Overview Intelligence Charts News Fundamentals

Latest News

businesswire.com

enGene to Participate in Upcoming Investor Conferences

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference Date: Thursday, February 26, 2026 Format: Presentation Time: 1:20 p.m. ET Leerink Partners 2026 Global Healthcare Conference Date: Monday, March 9, 2026 Format: Fireside chat Time: 8:00 a.m. ET Barclays 28th Ann.

businesswire.com

enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 2:30 p.m. ET. A live webcast of the fireside chat can be accessed on the "Events and Presentations” page under the “Investors” section of the enGene website at.

seekingalpha.com

enGene: Two Major Catalysts On Deck For 2nd Half Of 2026

enGene Holdings (ENGN) maintains a Buy rating, driven by positive preliminary data and two major catalysts expected in 2H 2026. ENGN's detalimogene gene therapy achieved a 62% 6-month complete response rate in BCG-unresponsive, high-risk NMIBC with CIS post-amendment. ENGN is positioned as a potential first-line, best-in-class option for BCG-unresponsive NMIBC, offering ease of use and strong tolerability.

defenseworld.net

enGene (NASDAQ:ENGN) Reaches New 12-Month High – Time to Buy?

enGene Holdings Inc. (NASDAQ: ENGN - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Friday. The company traded as high as $11.26 and last traded at $11.11, with a volume of 180580 shares traded. The stock had previously closed at $10.64. Analyst Upgrades and Downgrades Several equities analysts have

businesswire.com

enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it has entered into an amendment to an amended and restated loan and security agreement (as amended, the “Loan Agreement”) with two of its subsidiaries and Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”), as agent, for up to US$125 million. Access to the additional non-dilutive capital strengthens enGene's balance sheet.

gurufocus.com

Market Today: WBD Bid, Alphabet Energy Deal, Uber Robotaxis

Stock News Paramount ups WBD bid financing: Paramount Skydance (PSKY) said Larry Ellison will personally guarantee $40.4B of equity for its $30/share all-cash h

businesswire.com

enGene Reports Full Year 2025 Financial Results and Provides Business Update

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the full year ended October 31, 2025, and provided a business update. “We are closing 2025 in a position of strength: enrollment in LEGEND's pivotal cohort is complete and the recent data update from the LEGEND pivotal cohort supports an emerging, competitive profile for the use of detalimogene as the.

businesswire.com

enGene's Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has selected detalimogene voraplasmid (also known as detalimogene and previously EG-70) to participate in the Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) Program. Detalimogene is a novel, investigational, non-viral gene therapy for patie.

businesswire.com

enGene to Present at the Piper Sandler 37th Annual Healthcare Conference

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that Alex Nichols, Ph.D., Chief Strategy and Operations Officer, will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025, at 12:10 p.m. ET. A webcast of the presentation can be accessed on the "Events and Presentations” page under the “Investors” section of the enGene website at www.engene.com and wil.

businesswire.com

enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced the pricing of its previously announced underwritten public offering of 12,558,823 common shares at a public offering price of $8.50 per share and pre-funded warrants to purchase 2,735,295 shares of its common shares at an offering price of $8.4999 per pre-funded warrant, in each case, before underwriting discounts and commiss.

businesswire.com

enGene Announces Proposed Public Offering of Common Shares

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it has commenced an underwritten public offering of its common shares. All common shares to be sold in the offering will be offered by enGene. In addition, enGene intends to grant the underwriters a 30-day option to purchase up to a number of additional common shares equal to 15% of the total number of common shares sold.

seekingalpha.com

enGene Holdings: Still A Buy After A Massive Surge

enGene Holdings remains a Buy, driven by promising LEGEND trial data for detalimogene voraplasmid in non-muscle invasive bladder cancer. ENGN's phase 2 LEGEND trial showed a 63% complete response rate, comparable to ImmunityBio's Anktiva, positioning ENGN as a strong NMIBC contender. ENGN has a robust cash runway into 2027, supporting continued operations and potential approval without immediate fundraising concerns.

seekingalpha.com

enGene Holdings Inc. (ENGN) Discusses Preliminary Data From LEGEND Pivotal Cohort in High-Risk BCG-Unresponsive NMIBC Transcript

enGene Holdings Inc. ( ENGN ) Discusses Preliminary Data From LEGEND Pivotal Cohort in High-Risk BCG-Unresponsive NMIBC November 11, 2025 8:00 AM EST Company Participants Lauren Hopfer Ronald H. Cooper - President, CEO & Director Hussein Sweiti - Chief Medical Officer Conference Call Participants Suzanne Merrill Yanan Zhu - Wells Fargo Securities, LLC, Research Division Judah Frommer - Morgan Stanley, Research Division Sean McCutcheon - Raymond James & Associates, Inc., Research Division Mani Foroohar - Leerink Partners LLC, Research Division Paul Jeng - Guggenheim Securities, LLC, Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Silvan Tuerkcan - Citizens JMP Securities, LLC, Research Division Andres Maldonado - H.C.

benzinga.com

EnGene Encouraged By Promising Response Rates In Bladder Cancer Trial

enGene Holdings Inc. (NASDAQ:ENGN) stock is edging higher on Tuesday, with a session volume of 18.62 million compared to an average volume of 266.85 thousand, as per data from Benzinga Pro.

businesswire.com

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported additional preliminary data from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid (also known as detalimogene and previously EG-70) in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients with carcinoma in situ (CIS) with or without conco.

businesswire.com

enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a conference call and webcast tomorrow, November 11, 2025, at 8:00 a.m. ET to discuss new preliminary data from its pivotal cohort in the ongoing LEGEND trial of its novel, non-viral gene therapy candidate, detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with high-ri.

businesswire.com

enGene to Participate in Upcoming Investor Conferences

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences in November: Guggenheim 2nd Annual Healthcare Innovation Conference Date: Tuesday, November 11, 2025 Time: 12:30 p.m. ET Stifel 2025 Healthcare Conference Date: Wednesday, November 12, 2025 Time: 2:00 p.m. ET Jefferies Global Healthcare Conference in London Date: Tuesday,.

businesswire.com

enGene Named a BioSpace 2026 Best Places to Work Winner

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (“enGene” or the “Company”) (Nasdaq: ENGN), a clinical-stage, non-viral genetic medicines company, today announced that BioSpace has named the company to its 2026 Best Places to Work. enGene is among 50 U.S. operating employers recognized as one of the most desirable workplaces in the life sciences industry. “Recognition as a BioSpace Best Place to Work honors enGene's commitment to create a positive work environment, underpinned by our m.

businesswire.com

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to four newly-hired employees, including Hussein Sweiti, M.D., MSc, Chief Medical Officer, with a grant date of September 30, 2025. The inducement award for Dr. Sweiti consists of a non-qualified stock option to purchase an aggregate 600,000 of the Company's common shares. The inducement aw.

businesswire.com

enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicine company, today announced that Hussein Sweiti, M.D., MSc, was appointed Chief Medical Officer, effective September 29, 2025. Dr. Sweiti is a surgical oncologist and physician-scientist with more than 15 years of experience spanning clinical practice, oncology clinical research, global drug development, regulatory submissions, and medical affairs. He mos.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance